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Consensus Statements of the American College of Veterinary Internal Medicine (ACVIM) provide the
veterinary community with up-to-date information on the pathophysiology, diagnosis, and treatment of
clinically important animal diseases. The ACVIM Board of Regents oversees selection of relevant topics,
identiﬁcation of panel members with the expertise to draft the statements, and other aspects of assuring
the integrity of the process. The statements are derived from evidence-based medicine whenever possible
and the panel oﬀers interpretive comments when such evidence is inadequate or contradictory. A draft is
prepared by the panel, followed by solicitation of input by the ACVIM membership which may be incorporated into the statement. It is then submitted to the Journal of Veterinary Internal Medicine, where it
is edited before publication. The authors are solely responsible for the content of the statements.

Equine Protozoal Myeloencephalitis: An Updated Consensus
Statement with a Focus on Parasite Biology, Diagnosis, Treatment,
and Prevention
S.M. Reed, M. Furr, D.K. Howe, A.L. Johnson, R.J. MacKay, J.K. Morrow, N. Pusterla, and
S. Witonsky
Equine protozoal myeloencephalitis (EPM) remains an important neurologic disease of horses. There are no pathognomonic clinical signs for the disease. Aﬀected horses can have focal or multifocal central nervous system (CNS) disease.
EPM can be diﬃcult to diagnose antemortem. It is caused by either of 2 parasites, Sarcocystis neurona and Neospora hughesi,
with much less known about N. hughesi. Although risk factors such as transport stress and breed and age correlations have
been identiﬁed, biologic factors such as genetic predispositions of individual animals, and parasite-speciﬁc factors such as
strain diﬀerences in virulence, remain largely undetermined. This consensus statement update presents current published
knowledge of the parasite biology, host immune response, disease pathogenesis, epidemiology, and risk factors. Importantly,
the statement provides recommendations for EPM diagnosis, treatment, and prevention.
Key words: Encephalitis; Equine myeloencephalopathy; Equine neurologic; Equine protozoal disease; Myelitis; Neospora
hughesi; Sarcocystis neurona.

Parasite Biology and Disease Pathogenesis

E

PM was initially called “segmental myelitis” by
Rooney in Kentucky in 1970.1 The syndrome was
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Abbreviations:
BBB
CNS
CSF
CVSM
ELISA
EMND
EPM
FDA
IFAT
PYR
SAG
SDZ
Se
SIG
Sp
WB

blood–brain barrier
central nervous system
cerebrospinal ﬂuid
cervical vertebral stenotic myelopathy
enzyme-linked immunosorbent assay
equine motor neuron disease
equine protozoal myeloencephalitis
Food and Drug Administration
indirect ﬂuorescent antibody test
pyrimethamine
surface antigen
sulfadiazine
sensitivity (of a diagnostic test)
special interest group
speciﬁcity (of a diagnostic test)
Western blot

renamed “focal encephalitis-myelitis” because of brain
involvement. Prickett, Rooney, and others described 44
cases of the disease in 19682 and 52 cases of the disease
in 19701 at the annual meeting of the American Association of Equine Practitioners (AAEP). Protozoa were
ﬁrst observed in association with characteristic lesions
in 1974,3,4 and the disease was given its current name,
equine protozoal myeloencephalitis by Mayhew et al.,
who reported on 45 cases at the AAEP meeting in
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1976.5 It is now well established that EPM can be
caused by either Sarcocystis neurona6 or Neospora hughesi,7–11 although the majority of cases are because of
infection with S. neurona.
Sarcocystis neurona has a 2-host life cycle that alternates between the deﬁnitive host, and any of multiple
mammal intermediate hosts. The opossum Didelphis virginiana is the deﬁnitive host for S. neurona in North
America.12 As well, South American opossums can act
as deﬁnitive hosts for S. neurona in the southern hemisphere.13 Sexual reproduction by the parasite in the
intestinal epithelium of the infected opossum results in
the production of sporozoite-containing sporocysts that
are passed in the feces. The sporozoites are infectious
for the intermediate hosts, which include skunks,14 raccoons,15 armadillos,16 and cats.17 S. neurona forms
latent sarcocysts in the muscle tissue of the intermediate
host; sarcocyst-laden muscle is the source of infection
for the opossum. Opossums are commonly infected
with S. neurona18 and can generate signiﬁcant contamination of the environment in locations which they frequent.
Horses are infected with S. neurona by ingesting food
or water that has been contaminated with feces from an
infected opossum. Although S. neurona sarcocysts were
described in 1 case of a 4-month-old foal with clinical
signs of EPM,19 it is unlikely that horses are normal
intermediate hosts that contribute to the parasite’s life
cycle as S. neurona sarcocysts are not found typically in
tissues of these animals and equine carcasses are seldom
accessible to opossums. Importantly, S. neurona is not
transmitted horizontally between horses, nor can it be
transmitted to horses from nonequine intermediate
hosts. Antibodies against S. neurona in foals before
suckling have been reported,20,21 but vertical transmission of this parasite in horses is probably uncommon.
Thus, opossums are the major source of S. neurona
infection for horses. The exact mechanisms by which
S. neurona enters the CNS are not known, but are
thought to involve either infection of endothelial cells
or leukocytes.22–25
The complete life cycle of N. hughesi is unknown, so
all mode(s) of transmission of this parasite to horses
remain poorly understood. Canids are a deﬁnitive host
for the related species Neospora caninum,26 but it has
not been established that dogs or wild canids are a
deﬁnitive host for N. hughesi. Vertical transmission of
N. caninum is very eﬃcient in cattle, and several recent
studies indicate that N. hughesi can be transmitted
transplacentally in horses.27,28
All horses are believed to be susceptible to EPM, but
it is clear that not all horses that are infected with
S. neurona or N. hughesi will develop disease. Studies in
both mice and horses experimentally infected with
S. neurona have demonstrated a critical role for the
immune response in preventing disease.29–32 Additionally, some EPM-aﬀected horses have demonstrated
altered immune responses, some of which are antigenspeciﬁc.25,33–35 As is clear from the ﬁnding that not all
horses have demonstrated decreased immune responses
with the methodology employed, the mechanisms

involving the development of disease remain poorly
understood.
It is unclear what inﬂuences the progression to severe
neurologic disease. Factors such as variations in protozoal inoculum and stress-induced immune suppression
have been implicated in the occurrence of EPM.36–38
However, eﬀorts to increase stress (ie, by additional
transport of infected horses) and treatment with
immunosuppressive steroids did not cause a concomitant increase in disease severity.39,40 Genetic variation
has been observed among the strains of S. neurona that
have been analyzed,41–43 and there is some evidence that
speciﬁc parasite genotypes may be particularly virulent
in marine mammals.44 However, such an association
was not apparent in isolates from horses suﬀering from
EPM.

Epidemiology and Risk Factors
A survey using postmortem data from 10 diagnostic
centers throughout the United States and Canada found
that a majority of EPM cases (61.8%) occurred in horses
that were 4 years old or less, whereas only 19.8% of the
EPM cases reviewed were in horses 8 years or older.45
Thoroughbreds, Standardbreds, and Quarter Horses
were most commonly observed, but no sex or seasonal
bias could be established. A smaller retrospective study
of 82 horses with histologic lesions compatible with EPM
suggested that EPM risk was highest among male Standardbreds.46 The mean age of aﬀected horses was 3.6 
2.8 years, similar to that found by Fayer et al.45
The seroprevalence of S. neurona in horses from the
United States has varied widely, ranging from as low as
15% to a high of 89%, depending on geographic location.47–51 Seroprevalences of 35.6% and 35.5% have
been observed in horses in Brazil and Argentina, respectively,52,53 thus indicating that this parasite commonly
infects horses in South America.
In general, the seroprevalence of N. hughesi is low in
horses. Serum antibodies against N. hughesi have been
reported in more than 10% of horses in some geographic regions,7,54–58 whereas other studies found antibodies against N. hughesi in much lower proportions of
horses (ie, <3%).52,53,59–62 Some of the variation may be
because of geographic diﬀerences, but studies that used
Western blot to conﬁrm serologic results have suggested
that seroprevalence to N. hughesi is commonly overestimated.57,59,62
A survey reported in 2001 by the National Animal
Health Monitoring System (NAHMS) estimated that
the annual incidence of EPM in horses 6 months of age
or older was 14  6 cases per 10,000 horses.63 While it
is now known that N. hughesi can cause neurologic disease in horses,7–11 the proportion of EPM cases attributable to this parasite species remains uncertain.
EPM usually occurs sporadically and seldom involves
more than 1 horse on a farm,5,64 although clusters of
cases can occur.65,66 A retrospective study found that
young horses (1–5 years) and older horses (>13 years)
had a higher risk of developing EPM,67 as observed
previously. EPM occurred the least in the winter, with
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the risk 3 times higher in spring and summer and 6
times higher in the fall. On a given premise, the presence of opossums (2.5-fold), previous diagnosis of EPM
(2.5-fold), and the presence of wooded areas (2-fold)
were also associated with increased risk of EPM. The
likelihood of EPM was reduced by one third when wildlife was prevented access to feed and by one-half when
a creek or river was present as a water source.
Immune suppression because of stress or advanced age
might predispose a horse to development of EPM.36
Stressful events such as heavy exercise, transport, injury,
surgery, or parturition have all been found to increase
the risk of EPM.67 Racehorses and show horses had a
higher risk of developing EPM compared to breeding
and pleasure horses. Not surprisingly, horses with EPM
that were treated with an anticoccidial drug were 10 times
more likely to improve than untreated horses.36

Clinical Signs
Clinical signs of EPM vary from acute to chronic
with insidious onset of focal or multifocal signs of neurologic disease involving the brain, brainstem, or spinal
cord.64 Initial signs might include dysphagia, evidence
of abnormal upper airway function, unusual or atypical
lameness, or even seizures.68 Severely aﬀected horses
might have diﬃculty standing, walking, or swallowing
and the disease can progress very rapidly. Occasionally,
the clinical signs stabilize, only to relapse days or weeks
later.
The variability of clinical signs is because of infection
of both white and gray matter at multiple sites in the
CNS. Signs of gray matter involvement include focal
muscle atrophy and severe muscle weakness, whereas
damage to white matter frequently results in ataxia and
weakness in limbs caudal to the site of infection. Early
signs of EPM such as stumbling and frequent interference between limbs can be confused with lameness.
Horses aﬀected with EPM commonly exhibit a gradual
progression in severity and range of clinical signs. In
some cases, however, a gradual onset can give way to a
sudden exacerbation in the severity of clinical illness,
resulting in recumbency.
The vital signs in aﬀected horses are usually normal
and animals appear bright and alert. Some horses with
EPM appear thin and mildly obtunded. Neurologic
examination often reveals asymmetric ataxia, weakness,
and spasticity involving all 4 limbs. Areas of hyporeﬂexia, hypalgesia, or complete sensory loss are occasionally
present. The most common signs of brain/brainstem
disease include obtundation, head tilt, facial nerve
paralysis, and diﬃculty in swallowing, although signs
are not necessarily limited to these areas.69

Recommendations for EPM Diagnosis
Deﬁnitive diagnosis of EPM requires postmortem conﬁrmation of protozoal infection of the CNS (see below).
For highest accuracy in antemortem diagnosis, the following steps are recommended. (1) The presence of clinical signs consistent with EPM should be conﬁrmed by
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conducting a thorough neurologic examination. (2) Other
potential causes should be ruled out using available tools
(eg, cervical radiography). (3) Immunodiagnostic testing
of serum and CSF should be conducted to conﬁrm
intrathecal antibody production against S. neurona or
N. hughesi. The ratio of antibody in serum to CSF will
reveal intrathecal antibodies in most cases of EPM. The
Goldman-Witmer coeﬃcient (C-value) or the antigenspeciﬁc antibody index (AI) should be applied for cases
that have ELISA titer results that are equivocal (ie, the
serum:CSF ratio equals the cut-oﬀ) or when a condition
that compromises the blood–brain barrier is suspected.
The SnSAG2, 4/3 ELISA serum:CSF titer ratio and
NhSAG1 ELISA serum:CSF titer ratio are the only tests
currently oﬀered commercially that provide information
regarding intrathecal antibody production based on
serum and CSF titers. The commercially available S. neurona and N. hughesi IFATs do determine antibody titers
in both the serum and CSF, but the laboratory does not
calculate ratios at this time.

Basis for Recommendations
In horses with clinical signs consistent with CNS disease, EPM should be considered as a diﬀerential.
Aﬀected horses should initially have a thorough neurologic examination to identify abnormalities, and localize
the lesion(s), which will allow one to further reﬁne the
diﬀerentials. This, combined with the use of appropriate
diagnostic tests, will assist in diagnosing EPM and ruling out other causes. Some of the most consistent/classic clinical signs include asymmetric gait and focal
muscle atrophy. When these signs are present, EPM
should be considered as a top diﬀerential diagnosis.
EPM-aﬀected horses are not painful, and rarely febrile,
unless comorbidities exist.

Diﬀerential Diagnoses
Almost all neurologic diseases in horses can have
clinical signs that are also present in EPM-aﬀected
horses. A thorough neurologic examination and diagnostic tests are needed to distinguish between EPM and
other diﬀerentials. Some diseases have other more consistent/classic signs that allow one to rule them in or
out. With cervical vertebral stenotic myelopathy
(CVSM), signs usually are symmetric and, typically, the
pelvic limbs are more severely aﬀected than the thoracic
limbs. Focal muscle atrophy is not common. Trauma
should also be considered as a diﬀerential cause of
spinal cord damage at any level, potentially causing
abnormal neurologic signs in 1 to all limbs.
In horses where there is a history of respiratory disease or an outbreak of abortion, EHV-1-associated neurologic disease should be considered as a more likely
diﬀerential. EHV-1-aﬀected horses may be febrile
shortly before or at the onset of neurologic signs. In the
EHV-1-aﬀected horses, neurologic signs typically manifest as symmetric, with primary pelvic limb weakness
and ataxia, bladder distention, usually without incontinence, and, more rarely, perineal hypalgesia, tail paraly-
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sis, fecal retention and in some cases incontinence as
well. Some aﬀected horses show rapidly progressing
signs of ataxia and can sometimes have cranial nerve
deﬁcits, often involving cranial nerves VII to XII. In
other cases, cerebral signs occur.
Another disease which should be considered as a differential diagnosis is equine motor neuron disease
(EMND). Aﬀected horses with early stages of disease
typically have severe limb weakness with muscle fasciculations and tremors. Horses with chronic EMND can
have widespread, profound, muscle atrophy.
Other diﬀerentials of spinal cord disease that can result
in similar clinical signs include extradural and spinal cord
tumors, epidural abscess, migrating metazoan parasites,
rabies, West Nile viral encephalomyelitis, equine degenerative myeloencephalopathy/neuroaxonal dystrophy, lead
poisoning, creeping indigo toxicity, Lyme neuro-borreliosis, vascular malformations, and discospondylopathies. If
aﬀected horses have signs of cranial nerve or brain
involvement, EPM should be considered as a diﬀerential.
Other rule outs include viral encephalomyelitides, neoplasia, head trauma, brain abscess, migrating parasites,
temporohyoid osteoarthropathy, polyneuritis equi,
cholesterol granuloma, metabolic derangement, and hepatoencephalopathy.

Postmortem Diagnosis
Conﬁrmation of EPM on postmortem examination is
based on demonstration of protozoa in CNS lesions,
although the diagnosis frequently is made presumptively
even when parasites are not detected if the characteristic
inﬂammatory changes are found. In 2 reported series,
organisms were seen in H&E sections of CNS tissue in
10 to 36% of suspected cases.46,70 Sensitivity was
increased from 20 to 51% by immunohistochemical
staining with antibody against S. neurona.70 Although it
has not been demonstrated experimentally, the use of
PCR to detect parasites in CNS tissues might aid postmortem diagnosis of EPM. There is decreased likelihood of ﬁnding parasites histologically in tissues from
aﬀected EPM horses that have been treated with
antiprotozoal drugs.46

Immunodiagnostic Testing
Overview
There are several immunodiagnostic tests currently in
use for EPM diagnosis. Importantly, these tests are an
adjunct to diagnosis and not the mainstay. Performing
serology as part of a general health screen or prepurchase examination is discouraged because of the very
low positive predictive value when a nonneurologic
horse is tested. In horses showing gait deﬁcits, EPM
serology should not be used to distinguish whether the
deﬁcits are caused by CNS or musculoskeletal disease.
Presence or absence of neurologic disease is determined
by the clinical examination, and serology can then help
reﬁne the diﬀerential diagnoses list for a neurologic
horse.

All commonly used tests are based on detection of
antiprotozoal antibodies in serum, CSF, or both. As
EPM occurs only in a small proportion of horses
infected with S. neurona,63 testing for serum antibodies
against S. neurona has minimal diagnostic value unless
the serologic results are negative (low positive predictive
value but high negative predictive value).71,72 However,
detection of serum antibodies against N. hughesi in a
neurologic horse has a higher positive predictive value
because of a much lower seroprevalence. A negative
serum test usually indicates that the horse has not been
infected and alternative diagnoses should be pursued or
that the EPM-suspect horse resides in a geographic area
of low exposure to the infecting parasite. However, a
recently infected horse might display clinical signs
before seroconversion, and repeated serologic testing in
10–14 days is indicated for horses with recent development of compatible clinical signs. Detection of antibodies in the CSF is more informative, but alone is not a
deﬁnitive indicator of EPM as there is passive transfer
of antibody across a healthy blood–brain barrier
(BBB).73 Additionally, blood contamination of CSF
samples can cause false-positive results.74–76 Logically,
horses with higher serum titers are more likely to have
detectable antibody levels in CSF in both of these circumstances.
Use of quantitative assays to detect intrathecal antibody production, indicating active parasite infection in
the CNS, provides an accurate approach for EPM diagnosis. The Goldman-Witmer coeﬃcient (C-value) and the
antigen-speciﬁc antibody index (AI) are tests of proportionality that assess whether the amount of pathogen-speciﬁc antibody in the CSF is greater than should be
present from normal passive transfer across the BBB.
These methods have been used in human medicine to
diagnose CNS infections caused by a variety of
pathogens,77–79 including the apicomplexan T. gondii.80,81
The value of these tests for EPM diagnosis was demonstrated initially with a sample set of 29 clinical cases.75
This study also showed that minor blood contamination
of the CSF sample (ie, up to 10,000 red cells per lL) will
not confound the assay results. Subsequently, 2 additional studies examining a more extensive collection of
horses with neurologic disease showed that a simple
serum:CSF antibody titer ratio was suﬃcient in many
cases for an accurate diagnosis of EPM caused by S. neurona.71,72 Although use of a serum:CSF titer ratio should
be equally eﬀective for diagnosis of EPM caused by
N. hughesi, an optimal serum:CSF titer ratio cut-oﬀ
needs to be established.

Available tests for EPM caused by S. neurona
Numerous serologic tests have become available during the past 2 decades to aid in the diagnosis of EPM
caused by S. neurona, including Western blot (WB),
indirect ﬂuorescent antibody test (IFAT), and surface
antigen (SAG) enzyme-linked immunosorbent assays
(ELISAs). Descriptions of testing options and reported
test performance are shown in Table 1.71,72,82–93 All
tests can be performed on serum or CSF, and none is
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Table 1.
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Performance of commercially available immunologic tests for antibodies against Sarcocystis neurona.
Reported performance

Test

Laboratory

WB87

EDS
UC Davis
IDEXX

mWB90

Michigan
State

IFAT83

UC Davis

SAG1 ELISA86

Antech

SAG2, 4/3
ELISA91

EDS

SAG1, 5, 6
ELISA92

Pathogenes

Interpretation
Band pattern read and
interpreted visually (subjective)
Results usually reported
as negative, weak positive,
low positive, or positive
Similar to standard WB (above)

Serum positive at ≥1:80
has ≥55% probabilitya of EPM
Serum negative at ≤1:40
has ≤33% probabilitya of EPM
CSF positive at ≥1:5
has 92% probabilitya of EPM
Serum positive at ≥1:16
but recommended cutoﬀ ≥1:32
Serum positive for
exposure at ≥1:250

Sample

Sensitivity (%)

Speciﬁcity (%)

Serum

8993, 8082, 8983

7193, 3882, 8783

CSF

8993, 8782

8993, 4482

Serum

10090, 8983

Serum

8983, 8384, 9489, 5971

9890a, 6983 (an.b., negative
cases not from
North America)
10083, 9784, 8589, 7171

CSF

10084, 9289, 6571

9984, 9089, 9871

Serum:CSF
titer ratio
Serum

6571

9871

6888, 1389

7188, 9789

Serum

30–86
(depending
on cutoﬀ)72, 7171
77–96
(depending
on cutoﬀ)72, 8871
86 (cutoﬀ ≤50)
or 93
(cutoﬀ ≤100)72, 8871
N/A

37–88 (depending
on cutoﬀ)72, 5071

CSF correlates well with
EPM if ≥1:40

CSF

Serum:CSF titer ratio very
predictive of EPM if ≤100

Serum:CSF
titer ratio

Serum positive at ≥1:8,
indicating infection

Serum

58–96 (depending
on cutoﬀ)72, 8671
96 (cutoﬀ ≤50) or 83
(cutoﬀ ≤100)72, 10071
N/A

WB, Western blot; mWB, modiﬁed Western blot; IFAT, indirect ﬂuorescent antibody test; SAG, surface antigen; ELISA, enzyme-linked
immunosorbent assay; EDS, Equine Diagnostic Solutions (Lexington, KY); UC Davis, University of California at Davis; EPM, equine
protozoal myeloencephalitis; CSF, cerebrospinal ﬂuid.
a
Based on pretest probability of 10%; see reference 85.

considered a gold standard. The WB, the ﬁrst immunodiagnostic test described for EPM, is a qualitative test
for antibodies against merozoite lysate. Its use has largely been supplanted by more quantitative tests, and
positive WB results have limited diagnostic utility.
However, negative WB results retain a high negative
predictive value. The IFAT is a quantitative (end-point
titer) test for antibodies against culture-derived whole
merozoites. Although serum titers obtained with the
IFAT have been used to predict the likelihood of EPM,
with higher titers suggesting greater probability of disease, studies that have used diverse collections of neurologic disease cases have shown that a serum titer alone
is a poor predictor of EPM.71,72 As a quantitative test,
the IFAT can be used to calculate a serum:CSF titer
ratio. However, this information is not routinely provided by the laboratory.
Most recent research has focused on the SAG ELISAs, quantitative (end-point titer) tests based on S. neurona surface antigens. These molecules have proven to
be good serologic targets in the assays because of their
high level of expression in the parasite and their
immunogenicity in infected horses.94–96 The SnSAG2
ELISA and the SnSAG4/3 ELISA accurately detect
antibodies against S. neurona in equine serum and CSF
samples88,91 and were used to demonstrate the value of

detecting intrathecal antibody production for EPM
diagnosis.71,72 An ELISA based on the SnSAG1 surface
protein has been described.86 However, this antigen is
not expressed by all strains of S. neurona,43 thereby
reducing its utility for serologic detection88 and EPM
diagnosis.89 An ELISA combining SnSAG1 with 2
additional SnSAGs (SnSAG5 and SnSAG6) is currently
oﬀered. However, no published reports describe validation of this assay, so it is unclear whether the test reliably detects antibodies to S. neurona.
Several studies have directly compared diﬀerent tests
for EPM (caused by S. neurona infection);71,83,89 these
publications and 3 unpublished studies presented at
ACVIM EPM Society SIGs97–99 are detailed in
Table 2.71,83,89,97–99 Although none of the studies examined all of the currently available tests, and the types of
samples utilized were variable, some general conclusions
are evident. Testing serum alone yielded less accurate
results than testing CSF alone or a serum:CSF titer
ratio, generally because of low speciﬁcity. One notable
exception was the SAG1 ELISA, which showed poor
sensitivity. Poor to fair test agreement was observed;
samples that were split and submitted to multiple labs
often had discrepant results. Three of the 6 comparison
studies evaluated the SAG2, 4/3 ELISA serum:CSF titer
ratio; in all 3 studies this test demonstrated the highest
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Table 2. Test comparisons related to EPM caused by Sarcocystis neurona
Tests (and samples)
compared

References

Sample origin

Results

Author conclusions

Duarte
et al. (2003)83





WB (serum)
mWB (serum)
IFAT (serum)



Necropsy cases
(9 positive, 39 negative)




Similar Se (89%) for all 3
Variable Sp
(IFAT 100%,
WB 87%, mWB 69%)

IFAT accuracy was
better than
WB tests.

Saville (2007)99






WB (serum)
mWB (serum)
IFAT (serum)
SAG1 ELISA
(serum)



Experimental cases
(1 Sarcocystis neurona
positive,
1 S. fayeri positive,
2 negative)
Clinical cases
(3 positive, 10 negative)
Necropsy case
(1 positive)



Variable for each case;
limited agreement
between tests

Necropsy cases
(9 positive, 17
negative)
Clinical cases
(10 positive, 29
negative)



Marked diﬀerence in Se
(IFAT serum 94%, IFAT
CSF 92%, SAG1
ELISA serum 13%)
Comparable Sp
(IFAT serum 85%, IFAT
CSF 90%, SAG1 ELISA
serum 97%)

WB and IFAT
were most
accurate, though
IFAT was
cross-reactive with
S. fayeri. mWB
tended to have
false-positive
results, whereas
SAG1 ELISA
tended to have
false-negative
results.
Low Se limited the
usefulness of the
SAG1 ELISA.

Necropsy cases
(7 positive, 5 negative)
Clinical cases
(6 positive, 2 negative)



Necropsy cases
(6 positive, 17
negative)
(n.b., 1 positive
case because of
Neospora hughesi
not S. neurona)



Necropsy cases
(11 positive,
28 negative)
Clinical cases
(6 positive,
14 negative)






Johnson
et al. (2010)89

Reed
et al. (2010)97









Renier
et al. (2012)98

Johnson
et al. (2013)71







IFAT
(serum, CSF)
SAG1 ELISA
(serum)



WB (CSF)
IFAT (serum)
SAG1 ELISA
(serum)
SAG2, 4/3 ELISA
(serum:CSF ratio)



IFAT (CSF)
SAG2, 4/3 ELISA
(serum:CSF ratio)



IFAT (serum, CSF,
serum:CSF ratio)
SAG2, 4/3 ELISA
(serum, CSF,
serum:CSF ratio)

















Variable Se (SAG2, 4/3
ELISA 90%, WB 90%,
IFAT 70%, SAG1
ELISA 55%)
Variable Sp (SAG2, 4/3
ELISA 100%, WB 95%,
SAG1 ELISA 90%,
IFAT 85%)

SAG2, 4/3 ELISA
serum:CSF ratio
was the most
accurate.

IFAT Se (100%) higher
than SAG2, 4/3 ELISA
Se (83%)
SAG2, 4/3 ELISA Sp
(100%) higher than
IFAT Sp (82%)

IFAT advantages
include testing for
N. hughesi and
use as serum
stand-alone test.
(n.b., SAG2, 4/3
ELISA
serum:CSF ratio
had higher overall
accuracy.)
Serum testing
alone was least
accurate; more
accurate methods
should be used.
SAG2, 4/3 ELISA
serum:CSF ratio
was most
accurate.

SAG2, 4/3 ELISA
serum:CSF ratio was
most accurate (97%)
IFAT CSF and
serum:CSF ratio also
had high accuracy (88%)

ACVIM, American College of Veterinary Internal Medicine; EPM, equine protozoal myeloencephalitis; SIG, special interest group; WB,
Western blot; mWB, modiﬁed Western blot; IFAT, indirect ﬂuorescent antibody test; SAG, surface antigen; ELISA, enzyme-linked
immunosorbent assay; Se, test sensitivity; Sp, test speciﬁcity; CSF, cerebrospinal ﬂuid.

overall accuracy as compared to the WB, IFAT, and
SAG1 ELISA. However, the SAG1, 5, 6 ELISA has
not yet been evaluated in any comparison study, so its
performance is currently unknown.

Available tests for EPM caused by N. hughesi
Two serologic assays are currently oﬀered for measuring antibodies against N. hughesi in equine samples
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Table 3.
Test

Commercially available immunologic tests for antibodies against Neospora hughesi.

Laboratory
100

IFAT
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UC Davis

Interpretation



Serum positive at ≥1:320;
negative at <1:40
CSF positive at ≥1:5

Reported performance




ELISA62

EDS





Serum positive at ≥1:500
CSF positive at ≥1:5
Serum:CSF titer ratio
provides most accurate
EPM diagnosis



Serum Se 100%, Sp 100%
at cutoﬀ of 1:640
Serum Se 100%, Sp 71%
at cutoﬀ of 1:320
Se and Sp estimates calculated
using samples from experimentally
infected horses, not EPM cases
Serum Se 94%, Sp 95% compared
to WB detection antibodies
(not EPM cases)

IFAT, indirect ﬂuorescent antibody test; ELISA, enzyme-linked immunosorbent assay; UC Davis, University of California at Davis;
EDS, Equine Diagnostic Solutions (Lexington, KY); CSF, cerebrospinal ﬂuid; EPM, equine protozoal myeloencephalitis; Se, sensitivity;
Sp, speciﬁcity; WB, Western blot.

(Table 3). An ELISA based on the major parasite surface antigen NhSAG162 is available from Equine Diagnostic Solutions, LLC, whereas an IFAT using whole
N. hughesi tachyzoites is oﬀered by the School of
Veterinary Medicine, University of California-Davis,
Veterinary Immunology Laboratory. Based on analysis
of 1006 random equine samples, the NhSAG1 ELISA
provides an estimated 94% sensitivity and 95% speciﬁcity for detecting antibodies against N. hughesi when
compared to Western blot results. The N. hughesi IFAT
sensitivity and speciﬁcity for detecting antibodies
against N. hughesi was reported to be 100% and
71.4%, respectively, at a cut-oﬀ of 1:320.100 These values were based on samples from 3 naturally infected, 7
experimentally infected, and 7 na€ıve horses. Of note,
neither the N. hughesi IFAT nor the NhSAG1 ELISA
have been fully validated for EPM diagnosis because of
an inadequate number of samples from EPM cases
caused by this parasite.

Recommendations for EPM Treatment and
Prevention
For treatment of EPM, it is recommended that 1 of
the FDA-approved anticoccidial drugs should be used
to control infection. The current FDA-approved drugs
are: a) Ponazuril (MarquisÒ; Merial, Inc., Duluth,
Georgia, 30096, USA); b) Diclazuril (ProtazilÒ; Merck
Animal Health, Madison, NJ, 07940, USA); and c) Sulfadiazine/Pyrimethamine (eg, ReBalanceÒ; PRN Pharmacal, Pensacola, Florida, 32514, USA). Additional
medical and supportive treatment should be provided
based on the severity of neurologic deﬁcits and complications arising from them.

Basis for Recommendations
Folate-Inhibiting Drugs
A combination of sulfadiazine and pyrimethamine
(SDZ/PYR) was 1 of the initial treatment for EPM.
Sulfonamides and pyrimethamine act synergistically by

interfering with folic acid metabolism and biosynthesis
of purine and pyrimidine nucleotides necessary for the
parasite’s survival.
A dosage regimen of PYR, 1 mg/kg PO q24 h, and
SDZ, 20 mg/kg PO q24 h for up to 6 months was the
earliest treatment for EPM. As dietary folate can interfere with the uptake of diaminopyrimidine drugs like
PYR,101 hay should not be fed for 2 hours before or
after treatment. PYR given PO to horses at 1 mg/kg/d
achieves a concentration of approximately 0.02 to
0.10 lg/mL in the CSF 4–6 h after administration.102
These experimental horses were allowed free access to
prairie hay, potentially reducing the bioavailability of
the drug.101 One of the PK characteristics is that
steady-state CSF concentrations of PYR can be
obtained after 4–6 hours after a single PO administered dose at 1 mg/kg/d. Further, short half-lives of
these compounds suggest that there will be large ﬂuctuations between peak and trough concentrations in
the CSF after single daily administration. Additionally,
as PYR is concentrated in CNS tissue relative to
plasma,103 the concentration at the desired site of
action might be >0.1 lg/mL. Mean peak CSF concentrations of sulfonamide after single or multiple dosing
(22–44 mg/kg) have been reported to be approximately
2–8 lg/mL.104 These drugs are available as an FDAapproved product (ReBalanceÒ; PRN Pharmacal).
Treatment eﬃcacy determined by clinical improvement
(2 or more improvement grades in the overall neurologic dysfunction) or reversion to a CSF negative status for S. neurona by immunoblot after 90 days of
treatment showed success in 60–70% of treated
horses.105
The toxic eﬀects of these drugs relate to the inhibition of folate synthesis and include bone marrow suppression,
anorexia,
urticaria,
and
self-limiting
diarrhea.102,106 Typically, there is progressive mild anemia (PCV in the low 20s) over a 6-month treatment
period; neutropenia and thrombocytopenia can be seen
in some cases as well. Pyrimethamine is teratogenic,
causing abortions in rats and congenital defects in
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pups.107 In addition, mares treated with pyrimethamine
in late pregnancy had a fatal syndrome observed in the
foals.108 Of the 4 mares, 3 had been supplemented with
folic acid. In other species, folic acid supplementation
will not prevent PYR-induced toxicosis109 or can even
exacerbate it.107 Therefore, the use of folic acid in
EPM-aﬀected horses treated with PYR cannot be justiﬁed.

Benzeneacetonitrile Drugs
Diclazuril and ponazuril, 2 members of the benzeneacetonitrile group of compounds, have been
approved by the FDA for treatment of EPM (US
FDA, ProtazilÒ antiprotozoal oral pellets. 1.56% diclazuril. Freedom of Information Summary; US FDA,
MarquisTM antiprotozoal oral paste. 15% w/w ponazuril. Freedom of Information Summary). With
demonstrated broad-spectrum anticoccidial activity in
many avian and mammalian species, these drugs are
related to the herbicide atrazine and are thought to target the parasite’s apicoplast organelle.110 The activity of
benzeneacetonitrile compounds against S. neurona and
N. caninum was initially shown in vitro.111–113 In horses,
pharmacokinetic studies have established that therapeutic steady-state concentrations of both diclazuril and
ponazuril are achieved by day 7 using labeled doses.114–
116
Moreover, use of a loading dose of ponazuril at
15 mg/kg resulted in steady-state concentrations in
blood and CSF by day 2.117 Furthermore, the concurrent administration of vegetable oil (1/2 cup) has shown
to increase the bioavailability of the FDA-approved
ponazuril product up to 15% (M. Furr, unpublished
observations). A loading dose for the FDA-approved
diclazuril product is not required and use of vegetable
oil does not increase its bioavailability (Hunyadi,
unpublished observations). The FDA-approved benzeneacetonitrile compounds exhibited eﬃcacy ranging
from 62 to 67% based on a neurologic examination
improvement of 1 grade or becoming negative to antibodies against S. neurona in serum and CSF.118
Because ponazuril and diclazuril are highly selective
against apicomplexan parasites, little to no toxicity is
to be expected at therapeutic doses.119
Duration of treatment will mainly depend on
response to antiprotozoal administration. While the
FDA-approved products are labeled for a treatment
course of 28 days, the majority of horses with EPM are
treated for a longer period of time, generally 6–8 weeks
or longer if clinical improvement is still apparent under
treatment. Discontinuation of antiprotozoal treatment
should be based on neurologic improvement. At this
time, antibody retesting in blood, CSF, or both is not
recommended to determine discontinuation of antiprotozoal drug administration.

Supportive Medical Treatment
Nonsteroidal anti-inﬂammatory drugs such as ﬂunixin
meglumine are frequently given to moderately or
severely aﬀected horses during the ﬁrst 3–7 days of

antiprotozoal treatment and in an attempt to prevent
worsening of neurologic deﬁcits during the early
antiprotozoal treatment. In the case of horses which are
in danger of falling down or exhibit signs of brain
involvement, the additional use of a short course of corticosteroids (0.1 mg/kg of dexamethasone once or twice
daily) and dimethyl sulfoxide (1 g/kg as a 10% solution
IV or by nasogastric tube once or twice daily) may control the inﬂammatory response and associated clinical
signs. Because the damaged CNS is susceptible to
oxidant injury, vitamin E (eg, 20 IU/kg daily per os) is
often used as an adjunct antioxidant treatment; it
remains to be determined experimentally whether this
practice is beneﬁcial.

Biologic Response Modiﬁers
Based on the assumption that horses that develop
EPM may be immune compromised, immunomodulators have anecdotally been included by some in treatment of the disease. The drugs used include levamisole
(1 mg/kg PO q12h for the ﬁrst 2 weeks of antiprotozoal
treatment and for the ﬁrst week of each month thereafter), killed Propionibacterium acnes (EqstimTM; Neogen, Lansing, MI), mycobacterial wall extract
(EquimuneÒ IV; Bioniche Animal Health Vetoquinol,
Belville, ON, Canada), inactivated parapox ovis virus
(Zylexis, Zoetis, Florham Park, NJ), and transfer factor
(4LifeÒ Transfer Factor, 4LifeResearch, Sandy, UT).
Because no studies have been conducted to evaluate
their eﬃcacy in EPM horses, no recommendations can
be made.

Prevention of EPM
Preventative approaches to EPM can be achieved by
decreasing stress along with reducing exposure to scat
from opossums. Practical approaches such not feeding
oﬀ the ground, providing separate sources of fresh
water for horses and preventing wildlife access to horse
pastures, paddocks, and stalls may also help reduce the
incidence of protozoal infections in horses.
Intermittent use of coccidiostatic and coccidiocidal
drugs is another approach used to prevent EPM. Two
prophylactic studies have looked at the use of ponazuril
after an experimental challenge.120,121 Treatment at
either 2.5 or 5.0 mg/kg PO q24h of ponazuril was
administered beginning 7 days before experimental challenge and continued for 28 days.120 In that study,
administration of ponazuril reduced clinical signs and
delayed seroconversion. Intermittent ponazuril paste
administration at 20 mg/kg PO every 7 days was associated with a signiﬁcantly decreased intrathecal antiS. neurona antibody response in horses experimentally
inoculated with S. neurona sporocysts.121 Collectively,
these 2 studies showed that daily or intermittent treatment with ponazuril minimized but did not eliminate
infection in horses experimentally infected with S. neurona. Recently, pharmacokinetics of daily low-dose
diclazuril (0.5 mg/kg PO q24h) given to adult healthy
horses were investigated.116 Diclazuril pellets, given at a
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low-dose, attained plasma and CSF concentrations
known to inhibit S. neurona and N. caninum in cell culture. The daily administration of a low-dose diclazuril
pellet topdressing to healthy foals from a farm with a
high exposure rate to S. neurona signiﬁcantly reduced
the monthly seroprevalence to S. neurona when compared to untreated foals.122 The authors of that study
suggested that the reported diﬀerence in temporal seroprevalence between treated and untreated foals was
likely because of the successful reduction of S. neurona
infection in foals receiving a daily low-dose diclazuril.
This preventive strategy has the potential to be used in
high-risk horses in an attempt to reduce the incidence
of EPM, although, future longitudinal studies will be
required before establishing a standard protocol.

Future directions
While considerable progress has been made as the
original EPM consensus statement in 2002, many questions remain unanswered. The highest priority areas
identiﬁed by the EPM organizing committee include:
(a) identifying whether S. neurona can establish a persistent but inapparent infection in the horse, (b) elucidating the nature of the immune response in
protection and disease, (c) determining how S. neurona
causes disease and whether organisms need to be present to cause pathologic changes and clinical signs, (d)
elucidating whether S. neurona parasite genotype inﬂuences infection and severity of signs, (e) identifying
whether co-infection with other pathogens can be a
contributing factor in EPM cases, (f) expanding the
fundamental knowledge of N. hughesi as a cause of
EPM, including identifying the deﬁnitive host, determining all modes of transmission and investigating the
host-pathogen relationship, including the protective
immune response. The Committee urges support for
the aforementioned projects as the knowledge gained
from these studies will lead to earlier and more accurate diagnosis, preventive approaches and more eﬃcacious treatments.

Summary
Based on the currently published information, it is
recommended that horses with neurologic signs consistent with EPM, because of S. neurona or N. hughesi,
have a thorough neurologic examination performed.
With this information, neurologic deﬁcits can be identiﬁed and the lesion(s) localized. Diﬀerentials can be
developed and appropriate diagnostic testing can be
performed to rule in EPM and rule out other diseases.
Current recommendations are for serum and CSF testing for S. neurona, N. hughesi, or both to identify
whether intrathecal antibody production is present.
Treatment recommendations for EPM include an FDAapproved treatment, as well as supportive care. Duration of treatment is based on resolution of clinical signs.
Horses that develop recurrent signs should be reassessed. As more knowledge is elucidated on the viru-
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lence of S. neurona and N. hughesi and the immune
phenotype is elicited, more accurate diagnose, more eﬃcacious treatments, and better preventative approaches
will be identiﬁed.
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